Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)MK-5684-01A Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Substudy 01A is part of a larger research study that is testing experimental treatments for metastatic castration-resistant prostate cancer...

This clinical trial is for participants who have metastatic castration-resistant prostate cancer (mCRPC) and whose cancer progressed on or after they were previously treated with next-generation Hormonal Agent (NHA).  Study of Investigational Drug, MK5684, in Participants with Metastatic Castration-Resistant Prostate Cancer  Patient Summary  This clinical trial is for participants who have metastatic castration-resistant prostate cancer (mCRPC) and whose cancer progressed on or after they were previously treated with a next-generation Hormonal Agent (NHA).  This trial is comparing the...

This clinical trial is for participants who have metastatic castration-resistant prostate cancer (mCRPC) and failed to respond to drugs or surgery to block the testes from making hormones and after treatment with other drugs for prostate cancer.  Study of Investigational Drug, MK5684, in Participants with Metastatic Castration-Resistant Prostate Cancer Patient Summary The Omaha-003 clinical trial is for participants who have metastatic castration-resistant prostate cancer (mCRPC) and failed to respond to drugs or surgery to block the testes from making hormones and after treatment with...